Alvesco® (ciclesonide) is a lung-activated inhaled corticosteroid (ICS) with a novel mechanism of action and unique pharmacology. Alvesco® is prescribed for the treatment of persistent asthma.
Alvesco® is formulated in solution and delivered via the familiar metered-dose inhaler (MDI) using a hydrofluoroalkane (HFA) propellant. It is available in two different inhalers:
- Alvesco® 80 Inhaler
- Alvesco® 160 Inhaler
According to the European SmPC the recommended dose of Alvesco®
is 160µg once-daily, which leads to asthma control in the majority of patients. However in severe asthmatics, 320µg twice-daily may be required to reduce the frequency of exacerbations. Dose reduction to 80µg once-daily may be an effective maintenance dose for some patients. Once control is achieved, the dose of Alvesco®
should be individualized and titrated to the minimum dose needed to maintain good asthma control1
Figure 1: Asthma management approach based on control1
Figure 2: Estimated equipotent daily doses of inhaled glucocorticosteroids for adults1
For more information, please refer to the European Summary of Product Characteristics (SmPC) for the Alvesco® 160 Inhaler and Alvesco® 80 Inhaler, which are available in this section.
Prescribing information varies from country to country according to the different requirements of local health regulatory authorities. Please ensure you consult your local prescribing information for full details.
Please find your local contact details from Takeda Worldwide database.
- From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2011. Available from: http://www.ginasthma.org/.